Browse TET1

Summary
SymbolTET1
Nametet methylcytosine dioxygenase 1
Aliases LCX; KIAA1676; bA119F7.1; leukemia-associated protein with a CXXC domain; ten-eleven translocation-1; CXXC6; ......
Chromosomal Location10q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF12851 Oxygenase domain of the 2OGFeDO superfamily
PF02008 CXXC zinc finger domain
Function

Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation. Methylation at the C5 position of cytosine bases is an epigenetic modification of the mammalian genome which plays an important role in transcriptional regulation. In addition to its role in DNA demethylation, plays a more general role in chromatin regulation. Preferentially binds to CpG-rich sequences at promoters of both transcriptionally active and Polycomb-repressed genes. Involved in the recruitment of the O-GlcNAc transferase OGT to CpG-rich transcription start sites of active genes, thereby promoting histone H2B GlcNAcylation by OGT. Also involved in transcription repression of a subset of genes through recruitment of transcriptional repressors to promoters. Involved in the balance between pluripotency and lineage commitment of cells it plays a role in embryonic stem cells maintenance and inner cell mass cell specification. Plays an important role in the tumorigenicity of glioblastoma cells. TET1-mediated production of 5hmC acts as a recruitment signal for the CHTOP-methylosome complex to selective sites on the chromosome, where it methylates H4R3 and activates the transcription of genes involved in glioblastomagenesis (PubMed:25284789).

> Gene Ontology
 
Biological Process GO:0001701 in utero embryonic development
GO:0001824 blastocyst development
GO:0001825 blastocyst formation
GO:0001826 inner cell mass cell differentiation
GO:0006211 5-methylcytosine catabolic process
GO:0006304 DNA modification
GO:0006342 chromatin silencing
GO:0006346 methylation-dependent chromatin silencing
GO:0006479 protein methylation
GO:0006486 protein glycosylation
GO:0006493 protein O-linked glycosylation
GO:0008213 protein alkylation
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0016458 gene silencing
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0019827 stem cell population maintenance
GO:0019857 5-methylcytosine metabolic process
GO:0031056 regulation of histone modification
GO:0031058 positive regulation of histone modification
GO:0031060 regulation of histone methylation
GO:0031062 positive regulation of histone methylation
GO:0031935 regulation of chromatin silencing
GO:0031936 negative regulation of chromatin silencing
GO:0032259 methylation
GO:0035510 DNA dealkylation
GO:0040029 regulation of gene expression, epigenetic
GO:0043413 macromolecule glycosylation
GO:0043414 macromolecule methylation
GO:0044270 cellular nitrogen compound catabolic process
GO:0044728 DNA methylation or demethylation
GO:0045814 negative regulation of gene expression, epigenetic
GO:0045815 positive regulation of gene expression, epigenetic
GO:0046700 heterocycle catabolic process
GO:0051052 regulation of DNA metabolic process
GO:0051053 negative regulation of DNA metabolic process
GO:0060968 regulation of gene silencing
GO:0060969 negative regulation of gene silencing
GO:0070085 glycosylation
GO:0070988 demethylation
GO:0070989 oxidative demethylation
GO:0072527 pyrimidine-containing compound metabolic process
GO:0072529 pyrimidine-containing compound catabolic process
GO:0080111 DNA demethylation
GO:0090308 regulation of methylation-dependent chromatin silencing
GO:0090310 negative regulation of methylation-dependent chromatin silencing
GO:0098727 maintenance of cell number
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1902275 regulation of chromatin organization
GO:1905268 negative regulation of chromatin organization
GO:1905269 positive regulation of chromatin organization
Molecular Function GO:0005506 iron ion binding
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0016706 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors
GO:0043566 structure-specific DNA binding
GO:0051213 dioxygenase activity
GO:0070579 methylcytosine dioxygenase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-212165: Epigenetic regulation of gene expression
R-HSA-74160: Gene Expression
R-HSA-5221030: TET1,2,3 and TDG demethylate DNA
Summary
SymbolTET1
Nametet methylcytosine dioxygenase 1
Aliases LCX; KIAA1676; bA119F7.1; leukemia-associated protein with a CXXC domain; ten-eleven translocation-1; CXXC6; ......
Chromosomal Location10q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TET1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTET1
Nametet methylcytosine dioxygenase 1
Aliases LCX; KIAA1676; bA119F7.1; leukemia-associated protein with a CXXC domain; ten-eleven translocation-1; CXXC6; ......
Chromosomal Location10q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TET1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTET1
Nametet methylcytosine dioxygenase 1
Aliases LCX; KIAA1676; bA119F7.1; leukemia-associated protein with a CXXC domain; ten-eleven translocation-1; CXXC6; ......
Chromosomal Location10q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TET1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1030.564
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1910.617
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0390.901
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2680.496
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0690.973
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5170.843
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1370.705
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2340.781
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0090.992
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0280.944
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2860.628
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1240.314
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TET1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382715.8015.80.037
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1614250250.103
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTET1
Nametet methylcytosine dioxygenase 1
Aliases LCX; KIAA1676; bA119F7.1; leukemia-associated protein with a CXXC domain; ten-eleven translocation-1; CXXC6; ......
Chromosomal Location10q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TET1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTET1
Nametet methylcytosine dioxygenase 1
Aliases LCX; KIAA1676; bA119F7.1; leukemia-associated protein with a CXXC domain; ten-eleven translocation-1; CXXC6; ......
Chromosomal Location10q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TET1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TET1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTET1
Nametet methylcytosine dioxygenase 1
Aliases LCX; KIAA1676; bA119F7.1; leukemia-associated protein with a CXXC domain; ten-eleven translocation-1; CXXC6; ......
Chromosomal Location10q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TET1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTET1
Nametet methylcytosine dioxygenase 1
Aliases LCX; KIAA1676; bA119F7.1; leukemia-associated protein with a CXXC domain; ten-eleven translocation-1; CXXC6; ......
Chromosomal Location10q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TET1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTET1
Nametet methylcytosine dioxygenase 1
Aliases LCX; KIAA1676; bA119F7.1; leukemia-associated protein with a CXXC domain; ten-eleven translocation-1; CXXC6; ......
Chromosomal Location10q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TET1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTET1
Nametet methylcytosine dioxygenase 1
Aliases LCX; KIAA1676; bA119F7.1; leukemia-associated protein with a CXXC domain; ten-eleven translocation-1; CXXC6; ......
Chromosomal Location10q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TET1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.